^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KPG-818

    i
    Other names: KPG-818, KPG 818
    Associations

    News

    Trials
    Company:
    Kangpu Biopharma
    Drug class:
    Cereblon modulator, CRL4-CRBN E3 ubiquitin ligase modulator
    Related drugs:
    Associations

    News

    Trials
    7ms
    Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE (clinicaltrials.gov)
    P1/2, N=64, Completed, Kangpu Biopharmaceuticals, Ltd. | Active, not recruiting --> Completed | Phase classification: P1b/2a --> P1/2 | Trial completion date: Dec 2023 --> Aug 2023
    Trial completion • Phase classification • Trial completion date
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    KPG-818
    9ms
    Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects (clinicaltrials.gov)
    P1, N=30, Recruiting, Kangpu Biopharmaceuticals, Ltd. | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    KPG-818
    over3years
    Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects (clinicaltrials.gov)
    P1, N=56, Recruiting, Kangpu Biopharmaceuticals, Ltd. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    KPG-818
    over4years
    [VIRTUAL] KPG-818, a novel cereblon modulator, inhibits hematological malignancies in preclinical models (AACR-II 2020)
    The clinical use of lenalidomide in multiple myeloma (MM), mantle cell lymphoma (MCL) and myelodysplastic syndromes (MDS) represents a significant advance in the treatment of hematological malignancies and has altered the landscape of the blood cancer therapy. Importantly, KPG-818 prolongs the survival of the mouse cohorts bearing systemic human H929 multiple myeloma in a dose-dependent manner. Moreover, KPG-818 shows favorable DMPK and toxicity profiles in pre-clinical IND enabling studies.In summary, these immune modulation, anti-angiogenesis and antitumor results encourage the further clinical evaluation of KPG-818 in patients with Multiple Myeloma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and other hematological malignancies.
    Preclinical
    |
    IL6 (Interleukin 6) • CRBN (Cereblon) • IL17RB (Interleukin 17 Receptor B)
    |
    lenalidomide • KPG-818